 twice as high in stage group 4 (ASIR 4.3 vs 1.9 per 100,000), (Stage 4 means cancer has spread to other parts of the body)
When compared with the general female population, incidence of melanoma of the skin in women before, during and after pregnancy was:
 around double in those aged 30-34, 35-39, and 40-44 in pregnancy (27, 40 and 59 per 100,000 respectively) than in the female population (14, 18 and 23 per 100,000)  more than twice as high in the least deprived quintile (ASIR 35 vs 16 per 100,000)  statistically significantly higher in stage group 1 (ASIR 20 vs 9 per 100,000) (Stage 1 means cancer is relatively small and contained within the organ it started in)
When compared with the general female population, incidence of cervical cancer in women before, during and after pregnancy was:
 almost 50% higher in those aged 25 to 29 (ASIR 31 vs 21 per 100,000)  almost twice as high in the most deprived quintile (ASIR 27 vs 15 per 100,000)  statistically significantly higher in stage group 1 (ASIR 8.9 vs 5.8 per 100,000)
The higher rates of pregnancy-associated cancers compared to the general female population may be due to frequent obstetric examinations which increases the chances of cancer detection.
Further work using a more robust maternity dataset would be required to ascertain timing of cancer diagnosis in relation to delivery.
Chapter 1: Introduction
The occurrence of cancer during pregnancy is uncommon with an incidence rate of approximately 1 in 1,000 pregnancies. 1 The rate of pregnancyassociated cancer is increasing and this is partly caused by a trend in delaying child bearing to an older age. 2 Pregnancy-associated cancer is generally defined as a diagnosis during pregnancy or up to one year after delivery. 2, 3 Some studies also include cancers diagnosed prior to pregnancy. 4 The incidence of different cancers in pregnant women varies between studies, and appears to be dependent on the underlying incidence of cancer within the population and age distribution of mothers. Breast, malignant melanoma, cervix, lymphoma, thyroid, haematological, ovarian, colon and central nervous system cancers are the most common cancers associated with pregnancy. 2, 5, 6, 7 There is a lack of national data in the UK concerning the number of women who are diagnosed with cancer during pregnancy. 3 In view of this, this report summarises data on cancers that are diagnosed in women during pregnancy in England.
Cancer registry data was linked to Hospital Episode Statistics Admitted Patient Care (HES APC) inpatient data to establish pregnancy-associated cancers. Incidence of pregnancy-associated cancers was then investigated for different age groups, by income deprivation, region of residence (Government Office Region, GOR), and stage at diagnosis.
Chapter 2: Methods

Data sources
All malignant cancers (excluding non-melanoma skin cancer), (ICD10 C00-C97 excl C44), diagnosed between 2012 and 2014 in residents of England were extracted from the Cancer Analysis System (CAS) held by the National Cancer Registration and Analysis Service (NCRAS) within Public Health England (PHE). These records were linked at patient level to the NHS admitted patient care (APC) Hospital Episode Statistics (HES) data for all patients diagnosed with cancer. NCRAS holds a cancer-related HES APC dataset which is linked to the cancer register. However, this dataset does not include information on conception dates or gestation, and as a result the cohort could not be defined using pregnancy dates, so instead is defined on dates of cancer diagnosis.
Population estimates used in the calculation for age-standardised rates in general female population were provided by Office for National Statistics (ONS) for England and Wales. Conceptions (pregnancies) data for the period 2012 to 2014 were provided by ONS. 
Study population
The study population included females aged 15 to 44 years diagnosed with malignant cancer from 2012 to 2014 who had a pregnancy or delivery code recorded in the HES inpatient dataset. Women who were diagnosed with cancer and had pregnancy or delivery related care one year before, during, or up to one year after a cancer diagnosis, were included. Where a patient had more than one tumour, the earliest diagnosed in the period was analysed, and all subsequent tumours were excluded. In this study, women who had a cancer diagnosed one year before, during, or up to one year after pregnancy are referred to as 'pregnant women'. 4 The International Classification of Diseases, 10th revision 9 was used to classify the following sites; malignant neoplasms (C00-C97), pregnancy, childbirth and the puerperium (O00-O99) and persons encountering health services in circumstances related to reproduction (Z30-Z39). The full list of ICD10 codes used is included in the appendix.
Study factors
Sociodemographic information analysed included age at cancer diagnosis, Government Office Region (GOR) of residence, based on postcode at time of diagnosis, and socio-economic deprivation (as recorded by the income domain of the Indices of Multiple Deprivation (IMD) 2015). 10 The Indices of Deprivation 2015 provide a relative measure of deprivation in small areas (Lower-layer Super Output Areas, (LSOAs)) across England. The areas were grouped into quintiles according to their deprivation score and were numbered from the least deprived (1) to the most deprived (5).
All cancers were staged using the TNM 11 classification including mapping from FIGO stage for gynaecological cancers. Staging is a way of describing where the cancer is located, the size of cancer and how far it has grown. Stage 1 means cancer is relatively small and contained within the organ it started in. Stage 2 and 3 means cancer is larger or has spread into nearby tissues or lymph nodes. Stage 4 means cancer has spread to another organ of the body.
Statistical analysis
Age-specific rates were calculated in five-year age groups ranging from 15 -19 through to 40 -44 for pregnant women and the general female population. Age-standardised rates together with 95% confidence intervals were calculated using the 2013 European Standard Population 12 by GOR of residence, stage group and deprivation quintile for pregnant women and the general female population.
Statistical significance was determined by assessing whether the confidence intervals overlap the benchmark value 13 (general female population rate).
Non-overlapping confidence intervals are considered as statistically significantly different.
Deprivation in pregnant women was calculated by assigning weights to the population with each quintile representing 20% of the total pregnancies. 14 Due to low counts of pregnancy-associated cancers, detailed analyses are presented only for cancers with total counts of around 500 cases or more over the study period. These cancers are: breast (ICD10 C50), malignant melanoma of skin (ICD10 C43) and cervical cancer (ICD10 C53).
Chapter 3: Results
Overall and by site
Between 2012 and 2014, a total of 3,272 pregnancy-associated cancers were identified in 2,503,174 pregnancies. The associated age-standardised incidence rate in pregnant women was 173 per 100,000 pregnancies. 24 women had 2 diagnoses of cancer over the study period. Of the 24 women with multiple diagnoses, 16 were diagnosed with the same type of cancer and 8 women had different cancer diagnoses. Under the assumption that each individual had only one primary diagnosis, the second cancer was excluded.
The most common cancers were breast (784 cases, 55 per 100,000), melanoma of skin (504 cases, 26 per 100,000), cervical (498 cases, 19 per 100,000), haematological (286 cases, 15 per 100,000), ovarian (240 cases, 11 per 100,000), colorectal and anus (188 cases, 9 per 100,000), (Table 1) . These cancers accounted for 76% of all cancers diagnosed in pregnancy. Rate is age-standardised rate per 100,000 female population; 95% CI is 95% confidence interval.
Breast cancer was the most commonly diagnosed cancer amongst both the general female population as well as pregnant women (Figure 1 ). Breast cancer, malignant melanoma of skin, cervical, haematological, ovarian and colorectal cancer incidence rates were statistically significantly higher in pregnant women when compared to the general female population. General female population Pregnant women GOR Age-standardised rates were significantly higher in pregnant women compared to the general female population in all the regions except for East of England and West Midlands ( Figure 2 and Table 2 ).
By age
Figure 3: Age-specific incidence rates and 95% confidence intervals for all cancers (ICD10 C00-C97 excl C44) in pregnant women and general female population by 5 year age group, 15-44 years, 2012-2014. Table  3 ). Rate is average annual age-standardised rate per 100,000 female population; 95% CI is 95% confidence interval.
* Insufficient cases to calculate rates for pregnant women and/or general female population.
Age-specific breast cancer incidence rates were highest in the older age groups for both pregnant women and the general female population ( Figure  4 ). In the 35 to 39 age group, breast cancer incidence rates were almost 50% higher in pregnant women (93, 95% CI 76-113) compared to the general female population (63, 95% CI 60-67). Figure 5 and Table 5 ). Rate is average annual age-standardised rate per 100,000 female population; 95% CI is 95% confidence interval.
* Insufficient cases to calculate rate for pregnant women and females in general population.
In the 25 to 29 age group, cervical cancer incidence rates were almost 50% higher in pregnant women (31, 95% CI 24-39) when compared to the general female population (21, 95% CI 19 -24), ( Figure 6 and Table 6 ). Rate is average annual age-standardised rate per 100,000 female population; 95% CI is 95% confidence interval.
By deprivation quintile
In the most deprived (fifth quintile) areas, age-standardised incidence rates for all cancers combined (excluding non-melanoma skin) were two-thirds higher in pregnant women when compared to the general female population ( Figure 7 and Table 7 ). Rate is average annual age-standardised rate per 100,000 female population; 95% CI is 95% confidence interval.
Incidence rates of breast cancer were not statistically significantly different in pregnant women and the general female population in any deprivation quintile ( Figure 8 and Table 8 ). Rate is average annual age-standardised rate per 100,000 female population; 95% CI is 95% confidence interval.
In the least deprived (quintile 1) areas, melanoma skin cancer incidence rates were double in pregnant women (35, 95% CI 21-54) when compared to the general female population (16, 95% CI 14-18). Rate is average annual age-standardised rate per 100,000 female population; 95% CI is 95% confidence interval.
In the most deprived (quintile 5) areas, cervical cancer incidence rates were almost double in pregnant women (27, 95% CI 16-41) when compared to the general female population (15, 95% CI 14-17). Incidence rates for all cancers were statistically significantly different in pregnant women and the general female population across all stage groups except for patients diagnosed with stage 3 disease ( Figure 11 and Table 11 ). Rate is average annual age-standardised rate per 100,000 female population; 95% CI is 95% confidence interval.
By stage of disease
Incidence rates of breast cancer were double in pregnant women (4.3, 95% CI 2.1 -7.5) diagnosed with stage 4 disease when compared to the general female population (1.9, 95% CI 1.6 -2.1), ( Figure 12 and Table 12 ). Rate is average annual age-standardised rate per 100,000 female population; 95% CI is 95% confidence interval.
* Insufficient cases to calculate rate for pregnant women.
Incidence rates for melanoma of skin were around double in pregnant women (20, 95% CI 15-25) when compared to the general female population (9, 95% CI 9-10) diagnosed with stage 1 disease ( Figure 13 and Table 13 ). Rate is average annual age-standardised rate per 100,000 female population; 95% CI is 95% confidence interval.
Incidence rates of cervical cancers were statistically significantly different in pregnant women (8.9, 95% CI 6.1 -12.3) and the general female population (5.8, 95% CI 5.4 -6.3) diagnosed with stage 1 disease ( Figure 14 and Table  14) . The age-standardised incidence rate of cancer in pregnant women was 173 per 100,000 pregnancies. The overall crude rate was 131 per 100,000 pregnancies which is higher than the generally reported rate of 100 per 100,000. 1, 4 Other studies 2, 15 have reported overall crude rates of 137 and 173
per 100,000. Differences in incidence rates can be largely explained by variations in the definitions of study populations. Some studies include diagnoses of malignant cancers 9 months before and 12 months after delivery 2, 4 and others up to 6 months after delivery. 16 This study included patients who had a delivery, pregnancy or delivery related event 12 months before or after cancer diagnosis.
Another reason for the wide range in incidences may be different data sources. Some studies use hospital records, 15 others use linked cancer registry, birth and hospital records, 2 and some use linked maternal/neonatal hospital discharge records, birth and death certificate records and case files in cancer registry. 4 In this study, linked cancer registration data and hospital admitted patient care records were used.
As seen in a similar study, 2 the results presented here showed that cancer rates in pregnant women were higher than in the general female population of the same age. Pregnancy increases most women's interaction with health services, increasing the likelihood of cancer diagnosis. 2 Another reason for the increase in rates in pregnant women may be due to physiological changes during pregnancy which stimulate cancer progression, resulting in earlier detection. 4 One study attributed higher rates of pregnancy-associated melanoma to endocrine and growth changes of pregnancy.
17
When compared with the general female population, incidence of melanoma of the skin in pregnant women was more than twice in the least deprived quintile. For breast cancers, incidence rates in pregnant women were not significantly different when compared to the general female population, across all deprivation quintiles. In general, higher incidence rates are associated with lower levels of deprivation for cancers of the breast and malignant melanoma of skin. 14, 18 Incidence rates of cervical cancer in the general population for all ages are known to be higher in the most deprived areas.
Incidence rates of breast cancer were double in pregnant women who were diagnosed with stage 4 disease when compared to the general female population ( Figure 12 ). Some studies 19, 20 have shown that pregnant women with breast cancer presented with more advanced disease and larger tumours. This was attributed to difficulties of diagnosing pregnancyassociated breast cancer among other reasons. 20 Melanoma skin cancer incidence rates were around double in pregnant women when compared to the general female population diagnosed at stage 1 ( Figure 13) . Similarly, incidence rates of cervical cancers were significantly higher in pregnant women when compared to the general female population diagnosed with stage 1 disease. Diagnosis of melanoma skin cancer 21 and cervical cancer 22 is more frequent in pregnant women due to obstetric examinations.
Results of this analysis should be interpreted with caution due to a number of limitations. The main limitation of our approach is that the HES data used in this study contained hospital records of patients who were admitted for pregnancy or delivery care. This data may be considered crude as HES does not include deliveries that take place at home.
The Maternity Services Data Set 23 (MSDS) contains complete events of pregnancy, including information on routine booking appointments, labour and delivery, and maternal or neonatal death. Use of MSDS may in future allow us to extract data on pregnant women and then establish whether they had a cancer diagnosis. It was not possible to use the MSDS in this analysis as it was recently set up and has data completeness and quality issues 24 (which are improving).
Availability of delivery date in MSDS would allow for analysis on timing of cancer diagnosis to delivery ie prenatal, at delivery or postpartum. One study 4 has shown that timing of diagnosis is affected by cancer type with the majority of breast, cervical, and thyroid being diagnosed in the postpartum year, while ovarian, Hodgkin's disease, and leukemia were diagnosed just before delivery. Another study 2 showed that timing of cancer diagnosis had an effect on pregnancy outcomes such as thromboembolic events, sepsis and severe morbidity. Availability of maternal death data would allow for analyses on survival by cancer type. Survival could be compared for women with cancer diagnosis before delivery, at delivery and at postpartum.
Another limitation is that we selected the first tumour per patient diagnosed within the study period. Choosing one tumour per pregnant women means the rate definitions in the numerator and the denominator for all cancers is the same, but differs when broken down by cancer type. However, as only 24 women had 2 diagnoses of cancer (same or different type) any effect is likely to be negligible. Finally, the calculated pregnancy rates could be slightly overestimated as the numerator included miscarriages, abortions, pregnancy and delivery related admissions etc and the denominator included pregnancy resulting in live/still births or legal abortions but did not include miscarriages.
Conclusions
Breast, malignant melanoma, cervical, haematological, ovarian and colorectal were the most common cancers diagnosed in pregnant women accounting for 76% of the total observed cases between 2012 and 2014. The higher rates of pregnancy-associated cancers compared to the general female population may be due to frequent obstetric examinations which increases the chance of cancer diagnosis. Our results must be interpreted with the limitations of the databases used. Overall however, the results of this study contribute to the understanding of cancer in pregnant women in England. 
